# A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN

> **NCT04306510** · PHASE4 · TERMINATED · sponsor: **Akcea Therapeutics** · enrollment: 8 (actual)

## Conditions studied

- Hereditary Transthyretin Amyloidosis With Polyneuropthy

## Interventions

- **DRUG:** TEGSEDI

## Key facts

- **NCT ID:** NCT04306510
- **Lead sponsor:** Akcea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-21
- **Primary completion:** 2024-03-20
- **Final completion:** 2024-03-20
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Withdrawal of TEGSEDI from sale was not related to any safety issues.
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04306510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04306510, "A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04306510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*